GleamWall
中文EN

MIRA MIRA PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1904286

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY100.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-135.7%
ROA-131.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.9%
Debt / equity0.00x
Current ratio16.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio-66.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$947,014$705,789$524,781$496,543$412,639$496,197$314,404$861,441
SG&A expense$465,014$450,330$578,698$5.33M$904,346$1.05M$1.49M$1.58M
Interest expense——————-$21,421-$38,105
Net income-$1.42M-$1.21M-$1.15M-$5.98M-$1.14M-$1.54M-$1.78M-$2.40M
EPS (basic)—-0.03-0.03—-1.18-0.09-0.11—
EPS (diluted)-0.03-0.03-0.03—-1.18-0.09-0.11—
Weighted avg. shares (diluted)————19.27M16.99M16.65M—
Banking
Net interest income$26,541$35,130$44,909$53,170$15,697$8,623$21,421$38,105
Balance sheet
Cash & equivalents$2.50M$3.61M$4.82M$6.35M$2.64M$730,475$1.21M$2.83M
Short-term investments$4.47M$4.50M$4.59M$4.68M$4.89M———
Current assets$7.23M$8.17M$9.43M$11.06M$7.60M$832,879$1.36M$2.89M
Total assets$7.27M$8.20M$9.46M$11.09M$7.63M$868,318$1.40M$2.92M
Current liabilities$426,176$40,823$114,761$702,068$83,926$298,459$106,173$723,349
Total liabilities$426,176$40,823$114,761$702,068$83,926$298,459$106,173$723,349
Shareholders' equity$6.84M$8.16M$9.35M$10.39M$7.55M$569,859$1.29M$2.20M
Shares outstanding42.02M42.02M42.02M41.94M39.51M17.39M16.81M16.56M
Cash flow statement
Operating cash flow-$1.30M-$1.21M-$1.20M-$1.14M-$1.10M-$799,651-$1.63M-$1.81M
Financing cash flow$194,191$0-$330,607$4.84M$3.01M$323,841$3,381$493,401
Stock-based compensation$101,623$21,876$107,590$4.56M$297,090$489,566$874,812$546,781

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.